Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- JSMO Announces Guidance on Prevention and Treatment of Tumor Lysis Syndrome; Rasburicase Recommended for High-risk Patients
August 22, 2013
- Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
- JASDI Conducting Survey on Inconsistencies in Package Inserts of Similar Drugs; Will Come Up with Improvement Proposal by Year-End
August 19, 2013
- JSGM Initiates Plan to Unify Brand Names of Generic Fixed-dose Combination Drugs to Prevent Medication Errors
August 19, 2013
- St. Marianna University School of Medicine Hospital Ends Use of Diovan for Patients
August 16, 2013
- British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
- Japan Hypertension Society Sets Up Ethics Committee amid Diovan Fuss
August 8, 2013
- Japan Hypertension Society Deletes Citations of JIKEI Study from Treatment Guidelines
August 8, 2013
- NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
August 7, 2013
- Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
August 6, 2013
- The Lancet Has Not Received Notification from Jikei University on Investigation Findings: Spokesperson
August 1, 2013
- Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
July 31, 2013
- Role of Companies in Clinical Research Discussed at JAPhMed Annual Meeting
July 24, 2013
- University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
- Univ. Fails to Question Ex-Novartis Employee over KYOTO Study, Says Internal Probe “Has Limitations”
July 16, 2013
- “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
- Arzerra, Japan’s 1st Antibody for CLL, Will Expand Treatment Options: Dr Ogawa of Tokai Univ.
July 11, 2013
- Nearly 30% of RA Patients Show LDA 3 Years After Discontinuing Remicade: Prof. Tanaka of Univ. of Occupational and Environmental Health
July 11, 2013
- Orencia Particularly Suitable for Elderly RA Patients: Prof. Takeuchi of Keio University
July 8, 2013
- “No Data Manipulation” in VART Study of Diovan: Interim Report of Japanese Society of Hypertension
July 4, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…